I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV644882040US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 30, 2005 Signature

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Application No.: Not Yet Assigned

Filed: Concurrently Herewith

Yasuhiko Tabata et al.

Confirmation No.: N/A

Art Unit: N/A

For:

ISCHEMIA THERAPEUTIC AGENT

Examiner: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

**10/5**51607

Application No.: Not Yet Assigned

Docket No.: 17195/005001 JC20 Rec'd PCT/PTO 3 0 SEP 2005

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure

Statement shall not be construed to mean that a search has been made or that no other material

information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing

of this Information Disclosure statement shall not be construed to be an admission that any

patent, publication or other information referred to therein is "prior art" for this invention unless

specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37

CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Credit Card in the amount of \$450.00 covering the fee set forth

in 37 CFR 1.492(a), 1.492(c)(2), and 1.492(b)(3). Credit Card Payment Form SB-2038, with a

signature from an authorized cardholder, is enclosed. The Director is hereby authorized to

charge any deficiency in the fees filed, asserted to be filed or which should have been filed

herewith (or with any paper hereafter filed in this application by this firm) to our Deposit

Account No. 50-0591, under Order No. 17195/005001. A duplicate copy of this paper is

enclosed.

Dated: September 30, 2005

Respectfully submitted,

Jonathan P. Ósha

Registration No.: 33,986 #48,88

OSHA · LIANG LLP

1221 McKinney St., Suite 2800

Houston, Texas 77010

(713) 228-8600

(713) 228-8778 (Fax)

2

## JC20 RecypeTIFTO 3 0 SEP 2005

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
"	, octuber 101 101111 1 1 1 1 1 1 1 1 1 1 1 1 1 1			Application Number	Not Met Assigned & 7	
11	NFORMATION	N DI	SCLOSURE	Filing Date	Concurrently Herewith	
l s	TATEMENT I	BY /	APPLICANT	First Named Inventor	Yasuhiko Tabata	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	17195/005001	


U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	ВА	JP-2002-145797-A	05-22-2002	KOMEDA M		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Yasuhiko TABATA, "Tissue Engineering no tame no Saibo Zoshoku Inshi no Hoshutsu Seigyo", Associates of Keipcord Inc., 01/15/2003, Vol. 21, No. 1, pp. 13-23	
	СВ	Masaya YAMAMOTO et al., "Kekkan Shinsei o Yudo shita Kyoketsu Shinkin no Saibo Ishoku Chiryo", Ensho • Saisei, 2002, Vol. 22, No. 3, pp. 187-193	
	СС	Yasuhiko TABATA, "Saisei Igaku no Genjo to Tenbo Saibo Seicho Inshi no Johoka", Bio Clinica, 2000, Vol. 15, No. 14, pages 1093-1097	
	CD	Hiroshi SAKAKIBARA et al., "Shinzo Kekkan-kei Ryoiki ni okeru Drug Delivery System no Oyo", Gene & Medicine, 2002, Vol. 6, No. 3, pp 395-399	
	CE	Yasuhiko TABATA, "IV. Seitai Kogaku Gijutsu Drug Delivery System", tanpakushitsu Kakusan Koso, 2000, Vol. 45, No. 13, pp. 2179-2187	٠.
	CF	Masaya YAMAMOTO et al., "Polyion-Complex o Riyo shita Hydrogel kara no Shushu no Saibo Zoshoku Inshi no Johoka", Drug Delivery System, 1999, Vol. 14, No. 6, pp. 506-510	
	CG	Keiichi FUKUDA et al., "Tokushu Junkanki Ryoiki ni okeru Saisei Genjo to Tenbo", Medical Tribune, 2002, Vol. 35, No. 9, pp. 38-40	
	СН	Yasuhiko TABATA et al., "Basic FGF to Saibo Ishoku o Mochiita Kyobu Geka Ryoiki no Saisei Igaku", Japanese Journal of Thoracic and Cardiovascular Surgery, 2001, Vol. 49 special extra issue, page 145 PD2-2	
	CI	Yasuhiko TABATA, "Tokushu Saibo Koguku kara Soshiki Kogaku•Zoki Kogaku eno Tenkai Saibo Seicho Inshi no Hoshutsu Seigyo to Kekkan Shinsei", The Tissue Culture Engineering, 2001, Vol. 27, No. 10, pp 372-375	
	Cì	SAKAKIBARA, Y. et al., "Prevascularization with gelatin micro spheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation", J. Thoracic adn Cardiovascular Surgery, July 2002, Vol. 124, No.1 pp. 50-56	
	СК	YAMAMOTO, M. et al., "Improved therapeutic efficacy in cardiomyocyte transplanation for myocardial infarction with release system of basic fibroblast growth factor.", Artif. Organs., February 2003, Vol. 27, No. 2, pp 181-184	
	CL	IWAKURA, A. et al., "Basic fibroblast growth factor may improve devascularized sternal healing", Ann. Thorac. Surg., 2000, Vol, 70, pp 824-828	

Examiner Signature	Date Considered	•
118404		



	Under the Paperwork Reduc	tion Act	of 1995, no persons are required	Appro U.S. Patent and Traden	PTO/SB/08a/b (07-05)  oved for use through 07/31/2006. OMB 0651-0031  nark Office; U.S. DEPARTMENT OF COMMERCE  formation unless it contains a valid OMB control number.	
Sub	stitute for form 1449A/B/PT	0		Complete if Known		
l				Application Number	Not let (stanget )	
11	<b>NFORMATION</b>	I DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Yasuhiko Tabata	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	17195/005001	

	СМ	IWAKURA, A. et al., "Novel method to enhance sternal healing after harvesting bilateral internal thoracic arteries with use of basic fibroblast growth factor", Circulartion, 2000, Vol.	
1		102, No. 19 suppl. 3, p. III-307-III-311	
r	CN	TABATA, Y. et al., "Vascularization effect of basic fibroblast growth factor released from	
L		gelatin hydrogels with different biodegradabilities", Biometerials, 1999, Vol. 20, pp 2169-2175	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature Signat	Considered	
440404		

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.